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 1
 INTRODUCTION 
Coronary artery disease is one of the greatest killer diseases of mankind. It 
is the leading cause of death and disability in developed nations and is increasing 
rapidly in the developing world.1 The World Health Organization has drawn 
attention to the fact that coronary heart disease is our modern epidemic. The 
prevalence of coronary artery disease has progressively increased in India during 
the last half century. An aggressive lookout for the evaluation of coronary artery 
disease is required for some special risk factors apart from the conventional risk 
factors.  
The pathophysiological basis of acute coronary syndromes relies on the 
existence of vulnerable atherothrombotic plaques within the coronary arteries. 
Newer inflammatory and immunological mechanisms are emerging for the 
initiation and progression of atherosclerotic lesions. Anticardiolipin antibodies are 
a heterogenous family of autoantibodies found to play an important role in the 
patho physiology of atherosclerosis. They have been implicated as one of the most 
common acquired protein defects causing thrombosis.2 These antibodies have been 
associated with several forms of cardiovascular diseases such as myocardial 
infarction, stroke, carotid stenosis, and so on.  In India, a few studies have been 
conducted regarding the prevalence and incidence of the anticardiolipin 
antibodies. 
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AIM OF THE STUDY 
 
 
 
1. To find out the prevalence of beta2-glycoprotein I dependent anticardiolipin           
    antibodies (β2GPI) of isotype IgG and IgM in patients with ST segment                
    elevation myocardial infarction who were 55 years or younger. 
2. To find out the correlation between the conventional cardiovascular risk factors   
    and anticardiolipin antibodies.   
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REVIEW OF LITERATURE 
 
Acute myocardial infarction is a clinical syndrome that results from an 
injury to the myocardial tissue, which is caused by an imbalance between the 
myocardial oxygen supply and demand. Coronary atherosclerosis is an essential 
part of this syndrome in most of the patients. It is more likely to occur in patients 
with certain risk factors for this disease. Despite the fact that most cardiovascular 
events are explained by the conventional risk factors, the search for additional 
etiologic agents continues. In recent years, a number of new candidate risk factors 
or markers have been proposed as significant predictors of atherosclerosis and its 
complications.   
MAJOR INDEPENDENT RISK FACTORS 3 
• Advancing age 
• Tobacco smoking 
• Diabetes mellitus 
• Elevated total and low-density lipoprotein 
• Hypertension 
PREDISPOSING RISK FACTORS 
• Abdominal obesity 
• Ethnic atherosclerosis 
• Family history of premature coronary artery disease 
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• Obesity 
• Physical inactivity 
• Psychosocial factors 
NOVEL RISK FACTORS FOR ATHEROSCLEROTIC VASCULAR 
DISEASE 4 
1. Inflammatory markers 
• C-reactive protein 
• Interleukins (eg, IL-6) 
• Serum amyloid A 
• Vascular and cell adhesion molecules 
• Soluble CD40 ligand 
• Leukocyte count 
2. Hemostasis / Thrombosis markers 
• Fibrinogen 
• Von Willebrand factor antigen 
• Plasminogen activator inhibitor 1 (PAI-1) 
• Tissue-plasminogen activator 
• Factors V, VII, and VIII 
• D-dimer 
• Fibrinopeptide A 
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• Prothrombin fragment 1+2 
3. Platelet-related factors 
• Platelet aggregation 
• Platelet activity 
• Platelet size and volume 
4. Lipid-related factors 
• Small dense low-density lipoprotein 
• Lipoprotein (a) 
• Remnant lipoproteins 
• Apolipoproteins A1 and B 
• High-density lipoprotein subtypes 
• Oxidized LDL 
5. Other factors 
• Homocysteine 
• Lipoprotein-associated phospholipase A (2) 
• Microalbuminuria 
• Insulin resistance 
• PAI-1 genotype 
• Angiotensin-converting enzyme genotype 
•    ApoE genotype 
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• Infectious agents- cytomegalovirus, Chlamydia pneumonia, Helicobacter 
pylori, Herpes simplex virus 
 
         Atherosclerosis is a complex and indolent histopathological process, which 
is considered to be the most common underlying process in cardiovascular 
morbidity and mortality. In recent years it has become apparent that in addition to 
the traditional risk factors for atherosclerosis, this condition is also associated with 
infectious, inflammatory, and autoimmune factors.5 Atherosclerosis fulfills all the 
criteria delineated by Witebsky and Rose to define a condition as autoimmune in 
nature, and all arms of the immune system (including cellular components, 
autoantigens, and autoantibodies) play a part in atherosclerosis.6 
 
INVOLVEMENT OF CELLULAR COMPONENTS IN               
ATHEROSCLEROSIS 
     There is good evidence to suggest that cellular components of the immune 
system are involved in atherosclerosis. Studies using transgenic murine models 
show recruitment of mononuclear leucocytes through vascular leucocyte adhesion 
molecules and chemokines, differentiation of monocytes to macrophages, and 
endocytosis through scavenger receptors of oxidized low-density lipoprotein in 
atherogenesis. The importance of T cells in atherosclerosis is emphasized in a 
study in which CD4+ and CD8+ T cell depletion reduced fatty streak formation in 
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C57BL/6 mice, indicating that T cells aggravate fatty streak formation.7 A recent 
study emphasizes also the importance of specific lymphocytes. Lymphocytes 
obtained from low-density lipoprotein receptor deficient mice immunized with  
β2-glycoprotein I were transferred intraperitoneally into syngenic mice, producing 
larger fatty streaks in the recipients than in mice receiving lymphocytes from the 
control mice.8 T cell depletion of lymphocytes failed to induce this effect. Hence 
β2-glycoprotein I reactive T cells could promote atherogenesis. It is also of interest 
to determine whether atherosclerosis is mainly a T helper 1 or T helper 2 mediated 
condition.  
ASSOCIATION BETWEEN AUTOANTIBODIES AND 
ATHEROSCLEROSIS         
Apart from the involvement of cellular components in atheroscleosis, the evidence 
also suggests an association between autoantibodies and atherosclerosis.9 When a 
pathological state is multifactorial, it is not surprising that many play a part in its 
pathogenesis. 
Anti-oxidized low-density lipoprotein antibodies 
         Oxidation of low-density lipoprotein probably has an important role in the 
pathogenesis of atherosclerosis. It is not yet firmly established whether the 
immune response to oxidized low-density lipoprotein is pro-atherogenic or anti-
atherogenic in vivo, or, alternatively, whether it is merely an epiphenomenona for 
the presence of oxidized low-density lipoprotein. Anti-oxidized low-density 
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lipoprotein antibodies are raised in patients with early onset peripheral vascular 
disease, severe carotid atherosclerosis, 10 and angiographically verified coronary 
artery disease.11 12 
         In addition, raised levels of oxidized low-density lipoprotein were predictive 
of carotid atherosclerosis progression, 13 and myocardial infarction occurrence and 
mortality. 14 It was also found that raised levels of these antibodies occurred in 
patients with coronary artery disease compared with healthy controls regardless of 
the amount of coronary calcification. 15 
Anti-heat shock protein (HSP) 60/65 antibodies   
        Heat shock proteins are a family of proteins that shows a highly homologous 
sequence between different species from bacteria to man. Sonographic assessment 
of carotid atherosclerotic lesions showed that subjects with such lesions had 
significantly raised levels of anti-heat shock protein 65 antibodies compared with 
controls.16 
        In another study, C57BL/6 mice were injected with either heat shock protein 
65 (HSP65), HSP65-rich Mycobacterium tuberculosis, or phosphate buffered 
saline. Early atherosclerosis was significantly enhanced in mice fed a high 
cholesterol diet that were immunized with heat shock protein 65. Recently it has 
been suggested that IL4 has a crucial role in the progression of early 
atherosclerosis mediated by inflammation, as IL4 knockout mice immunized with 
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heat shock protein 65 had significantly less fatty streak formation than lesions in 
C57BL/6 mice.17 
INCLUSION OF BOTH CELLULAR AND HUMORAL COMPONENTS IN 
ATHEROSCLEROSIS 
        Atherosclerosis may also include both cellular and humoral components in its 
underlying pathophysiology, as occurs in many autoimmune diseases. A recent 
study determined the role of cellular and humoral immune responses to heat shock 
protein 65 in murine atherosclerosis. Lymph node cells, splenocytes, and IgG were 
obtained from the low-density deficient mice immunized with the heat shock 
protein.18 Adoptive transfer of heat shock protein reactive lymph node cells 
increased fatty streak formation in comparison with mice treated with bovine 
serum albumin primed cells. Similarly, repeated intrapeitoneal administration of 
IgG from the serum of heat shock protein65 immunised mice enhanced fatty streak 
formation in mice in comparison with controls.18 This study provides direct 
evidence for the pro-atherogenic properties of cellular and humoral immunity to 
heat shock protein 65, and raises the possibility that both arms of the immune 
system have a synergistic pro-atherogenic effect. 
 
ANTINUCLEAR ANTIBODIES IN ATHEROSCLEROSIS 
        Grainger and Bethel provided evidence for the presence of antinuclear 
antibodies in patients with radiological evidence of advanced atherosclerosis.19 
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Their discussion includes the possibility that these antibodies are merely an 
epiphenomenon or, alternatively, that they have a pathogenic role in 
atherosclerosis. Even though this study naturally does not provide answers to that 
crucial question, their finding itself is important and raises several thoughts and 
assumptions. 
        The accelerated atherosclerotic state found in patients with systemic lupus 
erythematosus and antiphospholipd syndrome might result from the higher 
frequency of traditional risk factors in these patients as well as the presence of 
anticardiolipin and anti-β2glycoprotein I antibodies.20 However antinuclear 
antibodies might also contribute to the accelerated atherosclerosis found in these 
patients. Further, the association of antinuclear antibodies with atherosclerosis 
raises the possibility that these antibodies play a part in atherogenesis or 
arteriosclerosis in other autoimmune and inflammatory states, such as vasculitides. 
As for other antibodies, the frequency of antinuclear antibodies is significantly 
higher in the elderly people (10-37%) than in the young (0-6%). 21 As coronary 
artery disease resulting from atherosclerosis is also found mostly in the elderly, 
antinuclear antibodies may be markers of advanced atherosclerosis or, 
alternatively, participate in its acceleration.  
 ATHEROSCLEROTIC PLAQUES        
           The collagenous portion of advanced atherosclerotic plaques, although the 
most prevalent, is also the most stable. In distinct contrast, the soft atheromatous 
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(lipid rich) component is particularly vulnerable to fissuring and rupture.22-26 A 
collagen rich fibrous cap that varies in stiffness, strength, and thickness covers the 
lipid core. Typically the fibrous cap is thinnest at its corners. These areas are also 
the most heavily infiltrated with foam cells. Progressive extracellular lipid 
accumulation as well as the progressive growth of the lipid core towards the 
luminal aspect can destabilize atherosclerotic plaques. 
THROMBOGENESIS 
Occlusive thrombosis occurring at a site of the plaque rupture is 
multifactorial in nature. First, thromboresistance is already impaired and a 
procoagulant environment exists; second, there is a sudden change in the vascular 
geometry favouring platelet-vessel wall interactions27; and third, thrombogenic 
components within the plaque are directly exposed to circulating blood cells and 
coagulant proteins.  
A classification of vascular injury preceding coronary arterial thrombosis 
has been proposed by Fuster and colleagues.28 It is divided into three distinct 
types. 
Type I:  
Injury is localized to the vascular endothelium and develops in areas of eccentric 
intimal thickening, blood flow alterations, and vascular branch points. Platelets 
adhere to these areas, contributing to the plaque growth.  
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Type II: 
 Injury is more extensive, involving deep plaque structures. As a result, platelet 
adherence, activation, and thrombosis are provoked. With the appropriate 
procoagulant environment, type II injury can precipitate occlusive thrombosis. 
Type III:  
Injury is characterized by extensive plaque disruption with exposure of a variety of 
plaque constituents and subendothelial connective tissues. There is a strong 
propensity toward thrombosis. This type of injury is the most common among 
patients with acute myocardial infarction.29 
       The normal functioning hemostatic mechanism represents a dynamic, finely 
tuned balance between procoagulant and anticoagulant forces. Fibrin is a common 
component of coronary arterial atherosclerotic plaques, suggesting that 
coagulation is a participant in the atherosclerotic process. Even in the earliest stage 
of development, a uniform pattern of antifibrin antibody binding is observed, 
suggesting that fibrinogen derived from the infiltration of plasma is converted to 
fibrin within the intima of the vessels. Advanced atherosclerotic plaques contain a 
localized banded pattern of antifibrin antibody binding, consistent with direct 
incorporation of polymerized fibrin within the fibrous cap.30 31 
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Platelets also are important participants in atherosclerosis. They can 
support macrophage (foam cell) formation in cultured aortic smooth muscle 
cells.32 It has also been observed that platelet depletion dramatically reduces the 
mitogenic response to vessel wall injury.33  
Thrombin, a serine protease has many potential effects on atherosclerosis, 
can induce macrophage interleukin 1 synthesis, a cytokine capable of provoking 
smooth muscle cell proliferation and expression of leucocyte adhesion molecules 
on the endothelial surface.  
A novel lipoprotein, LP (a), composed of LDL cholesterol and 
apolipoprotein (APO) a, has been shown by several investigative groups to 
compete with plasminogen for cell surface binding sites on monocytes, endothelial 
cells, and platelets.34 35 36 LP (a) can also adhere to fibrin to augment the 
conversion plasminogen to plasmin. Lastly, LP (a) induces the expression and 
secretion of plasminogen activator inhibitor, reducing vascular fibrinolytic 
capacity and thromboresistance. 
In acute myocardial infarction, occlusive intravascular thrombosis is the 
end result of profound local and systemic procoagulant factors. Some of the 
procoagulant states of importance are 37  
• Atherosclerotic coronary artery disease 
• Hyperlipidemia 
• Abnormal plasminogen activation 
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• Dysplasminogenemias 
• Antiphospholipid antibody syndrome 
• Antithrombin III deficiency 
• Protein C deficiency 
• Protein C resistance 
• Protein S deficiency 
• Malignancies 
• Myeloproliferative disorders 
• Homocystinuria 
• Paroxysmal nocturnal hemoglobinuria 
• Heparin (thrombocytopenia with thrombosis)        
• Synthetic antifibrinolytic agents 
• Prothrombin complex concentrates 
• Cocaine 
• Anabolic steroids 
• Oral contraceptive agents 
 
Autoimmunity has been implicated in a number of vascular processes 
including the initiation and the progression of atherosclerosis.38 The major 
antigenic targets for autoantibodies during atherogenesis are the oxidized lipids 
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such as the oxidized low-density lipoprotein, heat shock proteins (HSP) 60/65, and 
phospholipids such as cardiolipin.9, 38,39, 40  
Anticardiolipin antibodies have been associated with accelerated coronary 
atherosclerosis.15, 41, 42 They are a heterogenous family of autoantibodies that are 
directed against the negatively charged phospholipids (such as cardiolipin, 
phosphatidylserine, phosphatidylinositol), phospholipid-protein complexes, or 
plasma proteins (such as β2-glycoprotein I). 43 
Antiphospholipid antibodies are associated with an increased risk of arterial 
and venous thrombosis. Although myocardial infarction is not the most common 
type of arterial event that occurs with antiphospholipid antibodies, several 
prospective studies have provided evidence in favour of an increased risk with 
these antibodies. 
The concept of a protein target for antiphospholipid antibodies evolved 
from a series of independent reports in 1990. It became clear that the binding of 
the antibodies to cardiolipin required a cofactor which was subsequently identified 
as β2-glycoprotein I also known as apolipoprotein H.44-46 β2-glycoprotein I (β2GPI) 
is a highly glycosylated single chain plasma protein composed of 326 amino acids 
with a molecular weight of 50 kDa that appears to be the major, but not the only 
cofactor for the recognition of anionic phospholipid by antiphospholipid 
antibodies. The protein is a member of the complement control protein or short 
consensus repeat superfamily. There is evidence that β2-glycoprotein I itself may 
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be one of the major epitopes for antiphospholipid antibodies or may, in complex 
with phospholipids, form an antigenic site. The physiologic function of β2GP1 has 
not yet been established, but it has been proposed that the protein may play a 
scavenging role for exposed anionic phospholipid after apoptosis.47 48 
Following the discovery of the cofactor role for β2GPI, additional candidate 
cofactors and antigenic targets were identified.49 50 
ANTIGENIC TARGETS OF ANTIPHOSPHOLIPID ANTIBODIES 
Major antigens: 
• β2-glycoprotein I 
• Prothrombin    
Others: 
• Protein C  
• Protein S 
• Thrombomodulin 
• Annexin V 
• High/low molecular weight kininogen 
• Factor XI 
A number of studies demonstrated that the β2 glycoprotein I-dependent 
binding to phospholipids could be used to discriminate between autoimmune 
aniphospholipid antibodies and those found in patients following infections. 
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Antiphospholipid antibodies present in autoimmune diseases are thrombogenic 
and β2GPI dependent, as opposed to infection related antiphospholipid antibodies, 
which are thought less likely to be thrombogenic and are β2GPI independent.51 
The presence of β2GPI dependent antibodies was shown to be more specific for 
thrombosis than conventional anticardiolipin antibodies. 
CLASSIFICATION OF ANTIPHOSPHOLIPID THROMBOSIS 
SYNDROMES 
Antiphospholipid thrombosis syndrome associated with anticardiolipin 
antibodies is divided into one of six subgroups.52 Although there appears to be no 
correlation with the type or the titer of anticardiolipin antibody and the type of the 
syndrome, the subclassification of thrombosis and anti cardiolipin antibody 
patients into these groups is important for therapy.  
Type I syndrome 
Deep venous thrombosis with or without pulmonary embolus 
Type II syndrome 
Coronary artery thrombosis 
Peripheral artery thrombosis 
Aortic thrombosis 
Carotid artery thrombosis 
Type III syndrome 
Retinal artery thrombosis 
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Retinal vein thrombosis 
Cerebrovascular thrombosis 
Transient cerebral ischemic attack  
Type IV syndrome 
Mixture of types I, II, and III 
Type IV patients are rare 
Type V (fetal wastage) syndrome: 
Placental vascular thrombosis 
Maternal thrombocytopenia (uncommon) 
Fetal wastage common in first trimester 
Fetal wastage can occur in second and third trimester 
Type VI syndrome: 
Antiphospholipid antibody 
No apparent clinical manifestation. 
 
Most individuals with serum that reacts positively for antiphospholipid 
antibodies do not have systemic lupus, but may have a history of thrombosis. 
However, the antibodies may also appear transiently after tissue trauma, in 
infections, and as a response to exposure to certain drugs. 
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SITUATIONS IN WHICH ANTIPHOSPHOLIPID ANTIBODIES MAY BE  
DETECTED: 53 
Infections: 
• Acute self-limiting infections 
• Syphilis 
• Malaria 
• HIV infection 
• Hepatitis C 
Rheumatic and collagen vascular diseases 
• Systemic lupus erythematosus 
• Systemic sclerosis 
• Rheumatoid arthritis 
• Temporal arteritis 
• Psoriatic arthropathy 
• Sjogrens syndrome 
Thrombotic disease 
• Venous thromboembolic disease 
• Peripheral arterial occlusion 
• Microvascular thrombosis 
• Myocardial infarction and ischaemic heart disease 
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• After coronary artery bypass graft surgery 
• Valvular heart disease 
• Renal vascular disease 
• Pulmonary hypertension 
Disorders of the nervous system and eye 
• Thrombotic stroke 
• Transient cerebral ischaemia and amaurosis fugax 
• Sagittal-sinus thrombosis 
• Ischaemic optic neuropathy 
• Retinal venous occlusion 
• Multi-infarct dementia 
• Chorea 
• Guillain-barre syndrome 
• Transverse myelitis 
Obstetric disorders 
• Recurrent abortion 
• Fetal growth retardation 
• Early, severe pre-ecclampsia 
With medication 
• Phenothiazines 
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• Procainamide 
• Hydralazine 
• Phenytoin 
• Quinidine 
Miscellaneous 
• Livedo reticularis 
• Autoimmune thrombocytopenia 
• Autoimmune hemolytic anaemia 
• Bechet’s syndrome 
• Sickle-cell disease 
• Intravenous drug abuse 
ASSOCIATION OF ANTICARDIOLIPIN ANTIBODIES WITH 
VASCULAR INJURY 
POSSIBLE MECHANISMS 
• Endothelial activation 
• Accelerated atherosclerosis 
• Apoptosis 
• Autoimmunity 
• Genetic predisposition 
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ENDOTHELIAL ACTIVATION 
Anticardiolipin have been documented in subendothelial cardiac deposits54 
and in intimal-medial borders in isolated human atherosclerotic plaques. The 
mechanism of anticardiolipin-associated vasculopathy includes interaction of 
endothelial cells with platelets and antiphospholipids, to promote a cascade of 
reactions yielding recurrent local thrombosis and intimal hyperplasia.  
Anticardiolipin autoantibodies prompt a prothrombotic endothelial  
surface, 55 while the β2GPI anticardiolipin antibody complex activates endothelium 
in vitro.56 
Antiphospholipid antibody binding to endothelium induces in vitro up-
regulation of adhesion molecules, such as intracellular adhesion molecule-1 and 
extracellular adhesion molecule-1, stimulated by an autocrine loop of interleukin-
1β secretion.57 Platelet-endothelium interaction mediated by anticardiolipin may 
alter thromboxane A2-prostacyclin balance, leading to enhanced thrombosis and 
vasoconstriction.58 
Endothelin-1, which induces vasospasm and arterial occlusion, is released 
by the endothelium in response to antiphospholipid antibodies.59  
A mechanism similar to heparin-induced thrombocytopenia has also been 
suggested for anticardiolipin associated vascular occlusion and thrombosis.60 In 
addition to endothelin induced thrombosis, intimal hyperplasia plays a major part 
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in vascular occlusions. Endothelin, prompted by anticardiolipin, enhances 
endothelial cell proliferation in vitro.61  
Initial endothelial damage exposes the anionic phospholipids that react with 
the phospholipid binding proteins, such as the β2GPIor prothrombin. The 
simultaneous binding of anticardiolipin to cellular Fc receptor and phospholipid 
protein complex induces endothelial-platelet interaction resulting in thrombosis. 
ACCELERATED ATHEROSCLEROSIS 
An intriguing possible pathogenic role for anticardiolipin in vasculopathy is 
the cross reaction with oxidized low-density lipoprotein antibodies. Oxidized LDL 
is the principal lipoprotein found in atherosclerotic lesions, and it co-localizes with 
β2GPI and immunoreactive lymphocytes.62 Oxidized LDL binds to β2GPI and that 
these complexes can be found in the blood stream of patients with various 
autoimmune and chronic inflammatory diseases such as the systemic lupus 
erythematosus, chronic renal disease, diabetes mellitus, as well as in patients with 
myocardial infarction.63  
As phospholipids bear structural resemblance to LDL, anticardiolipin may cross-
react with antioxidised LDL.64 Each cardiolipin molecule contains four 
unsaturated fatty acids, highly susceptible to oxidation. Mice sera with high titers 
of oxidized LDL antibodies, bind cardiolipin effectively only after oxidation. 
Therefore oxidative events may also play a major part in anticardiolipin 
formation.65 On the one hand, oxidized LDL aggravates in vitro the clinical 
 24
manifestations of antiphospholipids and on the other hand, atherogenic effect of 
human lupus sera in vitro may be mediated by LDL-containing immune 
complexes.  LDL may also be involved in anticardiolipin associated vascular 
occlusion by inducing a prothrombotic state. LDL, itself may be a thrombogenic 
target of anticardiolipin, 66 and raised concentrations of lipoprotein (a) in patients 
with antiphospholipid antibodies may inhibit the fibrinolytic pathway. 
                                       
APOPTOSIS 
Hypercoagulability in persons with antiphospholipid antibodies may also be 
induced by apoptotic process. Alterations of the phospholipid phase of cell 
membranes during late apoptosis are immunogenic and associated with the 
production of antiphospholipid antibodies. These surface alterations also have an 
independent procoagulant activity.67 Apoptotic cells may promote coagulation 
directly or via atherosclerotic plaque dislodgement.  
Characteristic membrane blebbing, occurring in final stages of apoptosis 
may lead to the production of antiphospholipid antibodies and tissue factor 
procoagulant activity. Moreover, it has been claimed that via this pathway 
antiphospholipids may exert their hypercoagulability.67 Apoptotic inflammatory 
cells, such as the macrophages and T cells, are found abundantly in atherosclerotic 
plaques and may induce plaque instability. Endothelial cell apoptosis may lead to 
loss of anticoagulant activity and increased leukocyte and platelet adhesion, 
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resulting in rapid progression of the atherosclerotic and calcification process.67 On 
the other hand; antiphospholipid antibodies may enhance apoptosis, with nuclear 
DNA fragmentation, cell lysis, and membrane disruption.   
AUTOIMMUNITY 
Pathogenicity of antiphospholipids depends on the specificity, isotype, 
level, and duration of anticardiolipin.68 Cross-regulatory roles of immunity and 
autoimmunity have recently emerged in vasculopathic and atherosclerotic 
processes.69 A pre-requisite for this vascular autoimmunity is a humoral or cellular 
immune reactivity to self-antigens, 70 such as LDL turned immunogenic during 
oxidation and glycation and prompting T cell mediated immunity. 
GENETIC PREDISPOSITION 
Most anticardiolipin are species-specific recognizing only human plasma. 
They are associated with class 2 major histocompatibility complex and in 
particular the DQB1 locus and DRw53, and either DR4 (in Caucasians) or DR7 (in 
Latinos). Genetic factors probably play an important part in the thrombogenic 
mechanism of antiphospholipid antibodies.54 Therefore, anticardiolipin may occur 
in genetically or immunologically susceptible patients after a common infection or 
after recurrent endothelial insults and local thrombosis. 
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DIAGNOSIS 
The actual diagnosis of an ST segment elevation myocardial infarction does 
not rely on the electrocardiogram itself as the name might imply. The classic 
World Health Organization criteria71 requires that two of the following three 
elements be present for the diagnosis of acute myocardial infarction: 
1.  A history suggestive of coronary ischemia for a prolonged period (>30 min) 
2.  Evolutionary changes on serial electrocardiograms suggestive of myocardial 
infarction 
3.  A rise and fall in serum cardiac markers consistent with myonecrosis 
Only 2 out of 3 criteria are needed because of the wide variability in the pattern of 
patient presentation with acute myocardial infarction. 
 
THE JOINT EUROPEAN SOCIETY OF CARDIOLOGY (ESC) / 
AMERICAN COLLEGE OF CARDIOLOGY (ACC) definition of 
myocardial infarction72 
Criteria for acute, evolving or recent myocardial infarction 
Either one of the following criteria satisfies the diagnosis for an acute, evolving or 
recent myocardial infarction. 
1.Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of 
biochemical markers of myocardial necrosis with at least one of the following. 
• Ischemic symptoms 
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• Development of pathologic Q waves on the electrocardiogram. 
• ECG changes indicative of ischemia (ST segment elevation or depression) 
• Coronary artery intervention (eg. coronary angioplasty) 
2. Pathologic findings of an acute myocardial infarction.   
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MATERIALS AND METHODS 
The present study was an observational study conducted on a total of 63 
patients admitted into the intensive coronary care unit in the cardiology 
department at Govt. Stanley Medical College Hospital, Chennai. The period of 
study was from January 2005 to January 2006. 
Selection criteria 
Patients aged 55 years or younger, of either sex, who fulfilled the World 
Health Organization criteria71 for the diagnosis of acute myocardial infarction, 
were included in the study. We decided to have a cut off age of 55 for patients 
enrolled in the study group, since the prevalence of positive ELISA 
antiphospholipid tests increases with age. Further more, the prevalence of 
anticardiolipin antibodies in apparently healthy elderly individuals aged more than 
65 years ranged between 12-52%. 73,74 Equal number of age and sex matched 
controls were considered for comparison with our cases.  
By a thorough history taking, the presence of conventional cardiovascular 
risk factors such as hypertension, smoking, dyslipidemia, diabetes mellitus, and 
family history of premature coronary artery disease were obtained. Blood samples 
were taken immediately after hospitalization to determine the presence of β2- 
glycoprotein I dependent anticardiolipin antibodies. Laboratory recommendations 
regarding the transport of samples were strictly followed. The samples were 
analyzed at the Dept. of Immunology, Govt. Stanley Medical College, Chennai. 
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Since the serum lipid levels measured after the first 24 hours of acute myocardial 
infarction may be inconsistent and since, considerable numbers of patients were 
hospitalized beyond 24 hours, the lipid levels were not considered in the study.75 
 
DETAILS OF LABORATORY ANALYSIS FOR THE PRESENCE OF β2 -
GLYCOPROTEIN I DEPENDENT ANTICARDIOLIPIN ANTIBODIES 
 
NAME OF THE TEST 
It is an indirect solid phase enzyme immunoassay (ELISA) for the 
quantitative measurement of IgG and IgM class autoantibodies against cardiolipin 
in human serum or plasma. 
PRINCIPLE 
Highly purified cardiolipin is bound to microwells saturated with  
β2-glycoprotein I. Antibodies to these antigens, if present in diluted serum, bind in 
the microwells. Washing of the microwells removes unbound serum antibodies. 
Horseradish peroxidase (HRP) conjugated anti-human IgG and IgM 
immunologically bind to the bound patient antibodies forming a 
conjugate/antibody/antigen complex. Washing the microwells removes unbound 
conjugate. An enzyme substrate in the presence of bound conjugate hydrolyzes to 
form a blue color. The addition of an acid stops the reaction forming a yellow end 
product. The intensity of this yellow color is measured photometrically at 450 nm. 
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The amount of color is directly proportional to the concentration of IgG and IgM 
antibodies present in the original sample. 
STORAGE AND STABILITY 
• Store the kit at 2-8 0C. 
• Keep microplate wells sealed in a dry bag with desiccants. 
• The reagents are stable until expiration of the kit. 
• Do not expose the test reagents to heat, sun or strong light during storage 
and usage. 
• Diluted sample buffer and wash buffer are stable for atleast 30 days when 
stored at 2-8 0C. 
MATERIALS REQUIRED 
Equipment 
• Microplate reader capable of end point measurements at 450 nm 
• Multi-channel dispenser or repeatable pipet for 100 µl 
• Vortex mixer 
• Laboratory timing device 
• Data reduction software 
Preparation of reagents 
• Distilled or deionised water 
• Graduated cylinder for 100 and 100 ml 
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• Plastic container for storage of the wash solution 
SPECIMEN COLLECTION, STORAGE AND HANDLING 
• Collect whole blood specimens using acceptable medical techniques to 
avoid hemolysis  
• Allow blood to clot and separate the serum by centrifugation. 
• Test serum should be clear and non-hemolysed. Contamination by 
hemolysis or lipemia is best avoided, but does not interfere with this assay. 
• Specimens may be refrigerated at 2-8 0C for up to 5 days or stored at –20 
0C for up to six months. 
• Avoid repeated freezing and thawing of serum samples. This may result in 
variable loss of autoantibody activity.             . 
• Testing of heat-inactivated sera is not recommended. 
PREPARATION OF THE REAGENTS 
Preparation of the sample buffer 
Dilute the contents of each vial of the sample buffer concentrate with 
distilled or deiodinised water to a final volume of 100 ml prior to use. Store 
refrigerated: stable at   2-8 0C for atleast 30 days after preparation or until the 
expiration date printed on the label.  
Preparation of the wash solution 
Dilute the contents of each vial of the buffered wash solution concentrate 
with distilled or deiodinised water to a final volume of 1000 ml prior to use. Store 
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refrigerated: stable at 2-8 0C for atleast 30 days after preparation or until the 
expiration date printed on the label.  
Sample preparation 
Dilute all patient samples 1:100 with sample buffer before assay. Therefore 
combine 10µl of sample with 990 µl of sample buffer in a polystyrene tube. Mix 
well. Controls are ready to use and need not be diluted.  
 
TEST PROCEDURE 
1. Prepare a sufficient number of microplate modules to accommodate 
controls and prediluted patient samples 
2. Pipet 100 µl of calibrators, controls and prediluted patient samples in 
duplicate into the wells. 
3. Incubate for 30 minutes at room temperature (20-28 0C). 
4. Discard the contents of the microwells and wash 3 times with 300 µl of 
wash solution. 
5. Dispense 100 µl of enzyme conjugate into each well. 
6. Incubate for 15 minutes at room temperature. 
7. Discard the contents of the microwells and wash 3 times with 300 µl of 
wash solution. 
 
 33
 1 2 3 4 5 6 
A SA SE P1 P5       
B SA SE P1 P5     
C SB SF P2 P..     
D SB SF P2 P..     
E SC C1 P3        
F SC C1 P3        
G SD C2 P4      
H SD C2 P4      
  
         SA-SF:  Standards A to F 
         P1,P2 …:        Patient sample 1,2 …. 
         C1:  Positive control 
         C2:  Negative control 
 
8. Dispense 100 µl of TMB (3,3’, 5,5’-tatramethyl-benzidine) substrate 
solution into each well. 
9. Incubate for 15 minutes at room temperature. 
10. Add 100 µl of stop solution to each well of the modules and incubate for 15 
minutes at room temperature. 
 34
11. Read the optical density at 450 nm and calculate the results. Bi-chromatic 
measurement with a reference at 600-690 nm is recommended.  
12. The developed color is stable for at least 30 minutes. Read optical densities 
during this time. 
INTERPRETATION OF RESULTS 
In a normal range study with serum samples from healthy blood donors the 
following ranges have been established with the anti-cardiolipin test 
                                    ANTI-CARDIOLIPIN ANTIBODIES 
 IgG (GPL U/ml) IgM (MPL U/ml) 
NORMAL <10 <7 
POSITIVE ≥10 ≥7 
 
Quality control 
This test is only valid if the optical density at 450 nm for positive control and 
negative control as well as for the calibrator A and F complies with the respective 
range indicated on the quality control certificate enclosed to each test kit. If any of 
these criteria is not met, results are invalid and the test should be repeated. 
Calculation of the results 
For anti-cardiolipin IgG and IgM, a 4-Parameter-Fit with lin-log coordinates for 
optical density and concentration is the data reduction method of choice. 
Smoothed Spline Approximation and log-log coordinates are also suitable. 
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Recommended Lin-Log plot 
First calculate the averaged optical densities for each calibrator well. Use lin-log 
graph paper and plot the averaged optical density of each calibrator versus the 
concentration. Draw the best fitting curve approximating the path of all calibrator 
points. The calibrator points may also be connected with straight-line segments. 
The concentration of unknowns may then be estimated from the calibration curve 
by interpolation. 
STATISTICAL METHODS 
Descriptive methods: 
The distribution of the β2-glycoprotein I dependent anticardiolipin antibodies 
between the cases and controls, as well as the distribution of the conventional 
cardiovascular risk factors in the study group were described using bar diagram 
and pie charts wherever appropriate.  
Analytical methods: 
The significance of the prevalence of β2-glycoprotein I dependent anticardiolipin 
antibodies in the cases and the controls was analyzed using the statistical methods, 
Pearson Chi square test and Yates corrected Chi square test. The correlation 
between the conventional cardiovascular risk factors and β2-glycoprotein I 
dependent anticardiolipin antibodies was done using the Chi square test. A ‘p’ 
value <0.05 was considered significant. 
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OBSERVATIONS AND RESULTS 
 
 
 
In the present study, among the 63 cases, the age distribution ranged from 29-55 
years, with a mean age of 44 years. Since age is a major risk factor for coronary 
artery disease (age>45 for males and >55 for females), the cases were subdivided 
into two groups with 45 as the line of demarcation between them. Acute 
myocardial infarction occurred predominantly in males when compared to females 
in our study. 
 
 
TABLE 1 
GENDER DISTRIBUTION OF THE STUDY POPULATION 
 
MALE  
No (%) 
FEMALE 
No (%) 
TOTAL 
STUDY GROUP 57 (90.5 %) 6 (9.5 %) 63 
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TABLE 2 
AGE DISTRIBUTION OF THE STUDY POPULATION 
 
AGE > 45 
 
No (%) 
AGE ≤ 45 
 
No (%) 
TOTAL 
STUDY GROUP 29 (46%) 34 (54%) 63 
 
The presence of the conventional cardiovascular risk factors in the study 
population and its distribution was analyzed. Of the four risk factors 
(hypertension, diabetes mellitus, smoking, and family history of premature 
coronary artery disease) that were considered, smoking was widely prevalent in 
the study group. 
 
TABLE 3 
DISTRIBUTION OF DIABETES MELLITUS AMONG THE CASES 
 
DIABETICS  
No (%) 
NON DIABETICS 
 
No (%) 
TOTAL 
STUDY GROUP 13 (20.6%) 50  (79.4%) 63 
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TABLE 4 
DISTRIBUTION OF HYPERTENSION AMONG THE CASES 
 
 
 
HYPERTENSIVES 
No (%) 
NON HYPERTENSIVES 
 
No (%) 
TOTAL 
STUDY 
GROUP 
14 (22 %) 49 (77.8%) 63 
 
 
 
TABLE 5 
DISTRIBUTION OF SMOKING AMONG THE CASES 
 
 
 
SMOKERS  
No (%) 
NON SMOKERS 
 
No (%) 
TOTAL 
STUDY 
GROUP 
38  (60.3%) 25 (39.7%) 63 
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TABLE 6 
FAMILY HISTORY OF PREMATURE CORONARY ARTERY DISEASE 
AMONG THE CASES 
FAMILY HISTORY OF 
PREMATURE CAD  
PRESENT ABSENT 
TOTAL 
STUDY GROUP 7 (11.1 %) 56 (88.9 %) 63 
 
 
 
The antibody positivity was compared between the cases and the controls. 
The β2-glycoprotein I dependant anticardiolipin antibodies were found to be 
positive in 17 patients in the myocardial infarction group whereas 3 people tested 
positive in the control group. The antibody positivity was statistically significant 
in the study group. 
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TABLE 7 
 
 
 
DISTRIBUTION OF THE β2GPI DEPENDENT ANTICARDIOLIPIN 
ANTIBODIES AMONG THE CASES AND CONTROLS 
 
 
 
ANTIBODY 
POSITIVITY 
No (%) 
ANTIBODY 
NEGATIVITY 
 
No (%) 
TOTAL 
 
STUDY GROUP 
17 (27%) 46 (73%) 63 
 
CONTROL 
GROUP 
3 (4.8%) 60 (95.2%) 63 
 
χ2 = 11.7     P = 0.001 statistically significant. 
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TABLE 8 
ISOTYPE DISTRIBUTION OF ANTIBODY POSITIVITY IN 
CASES AND CONTROLS 
 
ANTIBODY 
POSITIVITY 
STUDY GROUP 
No 
CONTROL GROUP 
No 
IgG POSITIVITY 12 0 
IgM POSITIVITY 4 3 
IgG & IgM POSITIVITY 1 0 
 
TABLE 9 
IgG β2GPI ANTICARDIOLIPIN ANTIBODY IN CASES AND CONTROLS 
 
 
 
IgG 
POSITIVITY 
IgG 
NEGATIVITY TOTAL 
CASES 13 50 63 
CONTROLS 0 63 63 
TOTAL 13 113 126 
 
 
χ2 = 14.5     P = 0.001 statistically significant. 
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Isotype distribution of anticardiolipin antibodies namely IgG and IgM was 
studied in both the groups. IgG was the predominant isotype in the myocardial 
infarction group. A total of 12 patients were found to have IgG antibody positivity. 
Four patients showed IgM positivity while one had elevation of both the isotypes 
The significance of the antibody isotypes was then analyzed across both the 
groups. It was found that the isotype IgG positivity was statistically significant in 
the study group when compared to the control group. The IgM positivity did not 
show any significant difference between the two groups. 
TABLE 10 
IgM β2GPI ANTICARDIOLIPIN ANTIBODY IN CASES AND 
CONTROLS 
 
 
IgM 
POSITIVITY 
IgM 
NEGATIVITY TOTAL 
CASES 5 58 63 
CONTROLS 3 60 63 
TOTAL 8 118 126 
 
χ2y = O.53     P = 0.47         Not statistically significant. 
 
The conventional risk factors were then correlated with antibody positivity. 
Hypertension was the only factor that was significantly observed in the study 
group.  
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TABLE 11 
HYPERTENSION AND ANTICARDIOLIPIN POSITIVITY 
 
ANTIBODY 
POSITIVITY 
No 
ANTIBODY 
NEGATIVITY 
No 
TOTAL 
HYPERTENSIVES 7 7 14 
NON HYPERTENSIVES 10 39 49 
TOTAL 17 46 63 
 
χ2 = 4.8     P = 0.03 statistically significant 
TABLE 12 
DIABETES MELLITUS AND ANTICARDIOLIPIN POSITIVITY 
 
ANTIBODY 
POSITIVITY 
No 
ANTIBODY 
NEGATIVITY 
No 
TOTAL 
DIABETICS 4 9 13 
NON DIABETICS 13 37 50 
TOTAL 17 46 63 
 
χ2 = 0.12     P = 0.73      Not statistically significant 
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TABLE 13 
SMOKING AND ANTICARDIOLIPIN POSITIVITY 
 
ANTIBODY 
POSITIVITY 
No 
ANTIBODY 
NEGATIVITY 
No 
TOTAL 
SMOKERS 12 26 38 
NON SMOKERS 5 20 25 
TOTAL 17 46 63 
 
χ2 = 1.03     P = 0.3      Not statistically significant 
TABLE 14 
FAMILY HISTORY OF PREMATURE OF PREMATURE CAD AND 
ANTICARDIOLIPIN POSITIVITY 
FAMILY H/O 
PREMATURE CAD 
ANTIBODY 
POSITIVITY 
No 
ANTIBODY 
NEGATIVITY 
No 
TOTAL 
YES 2 5 7 
NO 15 41 56 
TOTAL 17 46 63 
 
χ2 = 0.01    P = 0.9      Not statistically significant 
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TABLE 15 
SEX AND ANTICARDIOLIPIN POSITIVITY 
 
ANTIBODY 
POSITIVITY 
No 
ANTIBODY 
NEGATIVITY 
No 
TOTAL 
MALE 15 42 57 
FEMALE 2 4 6 
TOTAL 17 46 63 
 
χ2 = 0.14    P = 0.7      Not statistically significant 
TABLE 16 
AGE AND ANTICARDIOLIPIN POSITIVITY 
 
ANTIBODY 
POSITIVITY 
No 
ANTIBODY 
NEGATIVITY 
No 
TOTAL 
AGE > 45 10 19 29 
AGE  ≤ 45 7 27 34 
TOTAL 17 46 63 
 
χ2 = 1.53    P = 0.21      Not statistically significant 
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DISCUSSION 
The correlation between raised antiphospholipid antibodies and arterial 
thromboembolism has been widely reported in the literature.76-78 However, the link 
between the raised levels of antiphospholipid antibodies and increased incidence 
of myocardial infarction is less recognized. 
Asherson79 reported 13 young patients aged 20 to 52 years with myocardial 
infarction (4%) out of 300 antiphospholipid antibody positive patients. The 
possible pathogenic relationship between these antibodies and myocardial 
infarction remains controversial. 
The rate of antiphospholipid antibodies in survivors of acute myocardial 
infarction ranges from 6% to 47%. 80-89 The prevalence of anticardiolipin 
antibodies in the healthy population ranges from 0% to 7.5%, depending on the 
particular assay and cut-off for positivity used, 90,91 and may reach 51.6% in the 
elderly.73 
A number of studies demonstrated that the β2 glycoprotein I-dependent    
(β2GPI) binding to phospholipids could be used to discriminate between 
autoimmune antiphospholipids and those found in patients following infections. 
Antiphospholipid antibodies present in autoimmune diseases are thrombogenic 
and β2GPI dependent, as opposed to infection related antiphospholipid antibodies, 
which are thought less likely to be thrombogenic and are β2GPI independent.51 
 47
The presence of β2GPI- dependent antibodies was shown to be more specific for 
thrombosis than conventional anticardiolipin antibodies. 
In the population that we examined, the prevalence of β2GPI-dependent 
anticardiolipin antibodies was 27%. This figure is significantly higher than the 
4.8%, observed in the control group (P =0.001), which is within the anticipated 
normal range. We found significantly increased levels of IgG β2GPI- dependent 
anticardiolipin antibodies (P =0.001) in our study group in comparison to the 
controls. In addition, a nonsignificant increase in the IgM β2GPI-dependent 
anticardiolipin antibodies (P =0.47) was found in the infarction group when 
compared with the controls.           
In our study, we found a notable, although not a significant difference in the 
frequencies of β2GPI-dependent anticardiolipin antibodies between the males and 
females (26.3% versus 33.3%, respectively). However, the females constituted 
only about 9.5% of the study population. 
          When we divided our patients into two groups based on age (ie,group I-
age>45, group II-age≤45) there was no significant difference in the frequencies of 
β2GPI-dependent anticardiolipin antibodies between them. 
           We found significantly higher frequencies of β2GPI dependent 
anticardiolipin antibodies among the patients with hypertension than in those 
without hypertension in the myocardial infarction group. However we did not find 
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any significant association between β2GPI-dependent anticardiolipin antibody 
positivity and other conventional cardiovascular risk factors like diabetes mellitus, 
smoking, and family history of premature coronary artery disease. 
Robin L.Brey et al 92 performed a nested case control study examining 
anticardiolipin as a risk factor for ischemic stroke and myocardial infarction by 
using stored frozen sera obtained from subjects enrolled in Honolulu Heart 
Program and were followed up for 20 years. The β2GPI-dependent anticardiolipin 
of the class IgG was significantly associated with both incident ischemic stroke 
and myocardial infarction. Men with a positive assay tended to be older and had 
lower total cholesterol levels. 
There are a good number of studies that looked into the prevalence of 
conventional anticardiolipin antibodies of isotypes IgG and IgM in the absence of 
β2GPI. Eli Zuckerman et al 93 found a high prevalence of anticardiolipin antibodies 
in relatively young survivors (aged 65 or younger) of acute myocardial infarction. 
They also found out that a high titer of anticardiolipin antibodies served as the 
only independent risk factor for subsequent thromboembolic events or a 
reinfarction after an acute myocardial infarction. Logistic regression analysis of 
coronary risk factors in the antibody positive group failed to show a statistically 
significant association. 
Jerzy Dropinski et al94 studied the possible association between 
antiphospholipid antibodies and carotid intima-medial thickness in young 
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survivors of myocardial infarction. 24% had an elevated antiphospholipid levels. 
There was a correlation between high antiphospholipid levels and intima-media 
thickness (P=0.01). Among the coronary risk factors only hypertension and 
smoking correlated with intima-media thickening. Tsai RT et al95 detected IgG and 
IgM anticardiolipin antibodies, each in 16.1% of myocardial infarction patients. 
Ferlazzo B et al.96 found significantly higher levels of anticardiolipin 
antibodies (P≤0.05) in 30% of patients with acute myocardial infarction and in 
35% of angina pectoris. Chandrashekhara S et al 97 studied the incidence of 
anticardiolipin in various thrombotic settings. Among the 302 patients evaluated 
for thrombosis, 20.77% had elevated IgG anticardiolipin antibodies. Of the 58 
patients who developed myocardial infarction, 13.79% tested positive for IgG 
anticardiolipin antibodies. 
A prospective study undertaken by Seijas M et al 98 showed that the 
anticardiolipin antibodies were higher among the acute myocardial infarction 
patients than among the general population although the presence of such 
antibodies did not increase the risk of new post-infarction thrombotic events. 
Hamsten’s study80 of 62 young survivors of myocardial infarction resulted in 21% 
of patients with raised anticardiolipin titers on two or more occasions. The 
association between the raised anitcardiolipin antibodies and the new thrombotic 
events during the 36-64 months of follow up was of borderline significance. 
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STUDIES ON THE PREVALENCE OF CONVENTIONAL 
ANTICARDIOLIPIN ANTIBODIES 
S.NO STUDY 
PREVALENCE OF 
ANTICARDIOLIPIN 
ANTIBODY 
POSITIVITY 
1 Eli Zuckerman et al 93 14% (either IgG or IgM) 
2 Jerzy Dropinski et al 94 24% (either IgG or IgM) 
3 Tsai RT et al 95 
IgG: 16.1% 
IgM: 16.1% 
IgG or IgM: 1.8% 
4 Ferlazzo B et al 96 30% (either IgG or IgM) 
5 Chandrashekhara S et al 97 13.8% (IgG) 
6 Seijas M et al 98 12% (either IgG or IgM) 
7 Singh K et al 99 4.2% (either IgG or IgM) 
8 Hamsten A et al 80 21% (IgG) 
9 Sletnes KE et al 81 6.2% (IgG) 
10 Phadke K V et al 100 6.8% (IgG) 
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. The Italian registry of antiphospholipid antibodies evaluated the natural history 
and the risk for thrombosis in a cohort of 360 unselected patients followed for 4 
years.101 Asymptomatic patients with anticardiolipin antibodies had an incidence 
of thrombosis of 0.9% per patient-year. 
There is evidence that β2GPI itself may be one of the major epitopes for 
antiphospholipid antibodies. There are a few reports on the possible role of β2GPI   
and anti-β2 GPI antibodies in coronary artey disease. Farsi et al.102 detected anti-β2 
GPI antibodies in a large proportion (29.7%) of coronary artery disease patients 
and in only 2.5% of controls. 
Veres K et al103 assessed the patients with acute coronary syndrome for the 
frequency and the type of antiphospholipid antibodies. The presence of 
antiphospholipid was also correlated with cardiovascular risk factors. Anti-β2 GPI 
antibodies were found in 14.4% of acute coronary syndrome patients (21.2% in the 
myocardial infarction subgroup). However no difference was observed regarding 
the conventional anticardiolipin antibodies between the patients and controls. They 
also did not find a significant association of anti-β2 GPI antibodies with any of the 
cardiovascular risk factors including hypertension, diabetes mellitus, smoking and 
lipid metabolism among their patients with acute coronary syndrome. 
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However the studies done by Sherer et al.39 and Limaye et al.42 did not 
support an association between anti-β2 GPI antibodies and coronary artery disease. 
There are also reports that fail to disclose associations between antibodies against 
cardiolipin and myocardial infarction or ischemic heart disease.81, 95, 99, 100 
Prospective controlled trials should shed light on this controversial subject. 
Two earlier prospective studies of dyslipidemic men reported that antibodies 
against cardiolipin and oxidized low-density lipoprotein are associated with an 
increased risk of myocardial infarction during a 5-year follow-up. Outi Vaarala et 
al104 studied, whether the presence of anticardiolipin antibodies carries a risk of 
myocardial infarction in a prospective cohort of middle-aged dyslipidemic men 
participating in the Helsinki Heart Study, a 5-year coronary primary prevention 
trial with gemfibrozil. 
The anticardiolipin antibody level (IgG) was significantly higher in patients than 
in controls (p< 0.005). Subjects with the antibody level in the highest quartile of 
distribution had a relative risk of myocardial infarction of 2 (95% confidence 
interval, 1.1 to 3.5) compared with the remainder of the population. This risk was 
independent of the confounding factors, such as age, smoking, systolic blood 
pressure, low-density lipoprotein, and high-density lipoprotein. Thus it was 
concluded that the presence of a high anticardiolipin antibody level was an 
independent risk factor for myocardial infarction or cardiac death. 
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The ability of anticardiolipin antibodies to predict myocardial infarction 
was investigated by Ruihua Wu et al14 in a prospective nested case control study in 
which healthy 50-year-old men were followed up for 20 years. Raised levels of 
antibodies against cardiolipin at 50 years of age correlated positively with 
myocardial infarction 10 to 20 years later. IgG and IgA antibodies against 
cardiolipin were associated with myocardial infarction between 50 to 60 years of 
life. Moreover, higher antibody levels were noted in those who died from acute 
myocardial infarction in comparison to those who survived. Only IgG and IgA 
antibodies against cardiolipin were associated with future myocardial infarction, 
whereas IgM antibodies were not. The risk for myocardial infarction associated 
with these antibodies was independent of other well-established predictors such as 
supine blood pressure, serum LDL/HDL ratio, body mass index and smoking.  
In conclusion, the association between anticardiolipin antibodies and 
myocardial infarction is relatively consistent except for some difference in opinion 
observed in few studies.81,95,99,100 There may be several reasons for these 
discrepancies. First, there are only few prospective studies, whereas a majority of 
the studies looked into the survivors of myocardial infarction or patients with 
established ischemic heart disease. Second, there are differences in the study 
populations. Third, differences in the test techniques may be involved. The study 
we conducted supported an association between anticardiolipin antibodies and 
myocardial infarction.   
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CONCLUSION 
 
The prevalence of β2glycoprotein I-dependent anticardiolipin antibodies was 
found to be 27%.  
 
IgG β2glycoprotein I-dependent anticardiolipin antibodies was the most relevant 
isotype associated with acute myocardial infarction.   
 
Hypertensives had a higher frequency of β2 glycoprotein I dependent 
anticardiolipin antibodies.  
 
β2 glycoprotein I dependent anticardiolipin antibodies did not show a significant 
association with other conventional risk factors considered. (diabetes mellitus, 
smoking, and family history of premature coronary artery disease). 
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PROFORMA 
Name  :                                                Age/Sex  : 
IP NO  :                                                Address  :  
History & Presenting complaints   
Chest pain  : 
Duration  : 
Breathlessness  : 
Palpitation  : 
DM  : 
HT  : 
Dyslipidemia : 
Smoking : 
Alcohol : 
Family h/o premature CAD : 
Drug history : 
H/O recurrent thromboembolic events : 
EXAMINATION 
Pulse rate:       BP: 
General examination: 
Cardiovascular system:      Respiratory system: 
Weight :                                     Height :                              BMI : 
 72
INVESTIGATIONS 
Total count :                                                            Differential count : P  L  E 
Hb% :                                                                      ESR : 
CRP :                                                                       VDRL : 
Blood sugar :                                                           Urea : 
Serum creatinine :                                                   Serum electrolytes : 
Total CK : 
CK – MB : 
 
Electrocardiogram : 
 
Echocardiogram : 
 
β2 glycoprotein I-dependent anticardiolipin antibodies 
                                        IgG  : 
                                        IgM  :            
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S.NO NAME GROUP AGE SEX IgG_ACL IgM_ACL
1 DEVAN 2 49 1 0 0
2 PUNNIYAKODI 2 40 1 0 0
3 KUPPAN 2 55 1 0 0
4 GOWRISHANKAR 2 32 1 0 0
5 ASHOK KUMAR 2 52 1 0 0
6 SUBBAIYA 2 49 1 0 0
7 ABDUL RAHIM 2 45 1 0 0
8 SHANMUGAM 2 45 1 0 0
9 SYED MOHAMMED 2 52 1 0 0
10 VASANTH 2 37 1 0 0
11 SENTHIL 2 52 1 0 0
12 SHANKAR 2 38 1 0 0
13 NAGAJYOTHI 2 53 0 0 0
14 NAZEER 2 40 1 0 0
15 JOHN 2 50 1 0 0
16 RAJESH 2 51 1 0 0
17 NAGARAJ 2 50 1 0 1
18 KANNAPAN 2 48 1 0 0
19 BHUVANESHWAR 2 52 1 0 0
20 GANGADARAN 2 53 1 0 0
21 PRAKASH 2 44 1 0 0
22 MALATHI 2 48 0 0 0
23 SUNDAR 2 50 1 0 0
24 VASANTHA 2 50 0 0 0
25 MURUGAN 2 50 1 0 0
26 JEYARAJ 2 45 1 0 0
27 RAJKUMAR 2 52 1 0 0
28 JEYANTHI 2 38 0 0 0
29 MURALI 2 50 1 0 0
30 ABRAHAM 2 37 1 0 1
31 JEYARAJ 2 47 1 0 0
32 SURENDAR 2 54 1 0 0
33 KANNAN 2 31 1 0 0
34 SHANKAR 2 54 1 0 0
35 KUMAR 2 38 1 0 0
36 NATARAJAN 2 42 1 0 0
37 VENKATESH 2 33 1 0 0
38 SAKTHIVEL 2 45 1 0 0
39 JEGANNATHAN 2 38 1 0 0
40 SREENIVASAN 2 37 1 0 0
41 RANGAN 2 38 1 0 0
42 SIVALINGAM 2 42 1 0 0
43 JEYACHANDRAN 2 46 1 0 0
44 RAMAN 2 36 1 0 0
45 LINGAM 2 35 1 0 0
46 DEVENDRAN 2 50 1 0 0
47 SRIRAM 2 40 1 0 0
48 THAVASI 2 52 1 0 0
49 RAGU 2 52 1 0 0
50 GAYATHRI 2 35 0 0 0
51 KARUPPAN 2 53 1 0 0
52 SAMY 2 35 1 0 0
53 NARAYANAN 2 52 1 0 0
54 GANGA 2 45 0 0 0
55 ANNAMALAI 2 48 1 0 0
56 ARUL 2 38 1 0 0
57 RAMAN 2 38 1 0 0
58 VIJAYKUMAR 2 34 1 0 0
59 GOPAL 2 32 1 0 0
60 RAMALINGAM 2 42 1 0 0
61 MOORTHY 2 30 1 0 0
62 THANGAVEL 2 29 1 0 0
63 SUDAKAR 2 52 1 0 1
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1 PUNNIYAKODI 1 49 1 ASMI 1 1 0 0 0 0 0 0.00 2.00
2 KUMAR 1 40 1 ASMI 0 0 1 1 0 0 0 0.00 1.00
3 GNANAMANI 1 55 1 AWMI 1 0 0 0 0 0 0 0.00 2.00
4 SRINIVASAN 1 32 1 AWMI 0 0 1 1 0 1 0 1.00 1.00
5 GNANANANDAN 1 52 1 AWMI 0 0 1 1 0 0 0 0.00 2.00
6 MOHAN 1 49 1 AWMI 1 1 0 0 1 1 0 1.00 2.00
7 NAZIMUDIN 1 45 1 IWMI 0 1 1 1 0 0 0 0.00 1.00
8 MANIVANNAN 1 45 1 IWMI 1 0 0 0 0 0 0 0.00 1.00
9 VENUGOPAL 1 52 1 IWMI 0 1 1 1 0 1 0 1.00 2.00
10 INDRA 1 37 0 ASMI 0 0 0 0 0 0 0 0.00 1.00
11 ISAC JAMES 1 52 1 IWMI/DMI 1 1 1 1 0 1 0 1.00 2.00
12 BALU 1 38 1 IWMI 0 0 0 1 0 0 0 0.00 1.00
13 BALARAMAN 1 53 1 IWMI/DMI 0 1 1 1 0 0 0 0.00 2.00
14 MURUGANANDAM 1 40 1 AWMI 0 0 1 1 0 1 0 1.00 1.00
15 BALAKRISHNAN 1 50 1 IWMI/DMI/RVMI 0 0 1 1 0 0 0 0.00 2.00
16 MOORTHY 1 51 1 AWMI 1 0 1 1 0 0 0 0.00 2.00
17 SUNDAR RAO 1 50 1 ASMI 1 1 0 1 0 0 0 0.00 2.00
18 BHERUDOSS 1 48 1 AWMI 1 1 1 0 0 0 1 1.00 2.00
19 SHABIR AHAMED 1 52 1 ILMI 0 1 0 0 0 1 1 1.00 2.00
20 KAJA MOIDEEN 1 53 1 IWMI/RVMI 0 1 1 1 0 1 0 1.00 2.00
21 GOVINDAN 1 44 1 ASMI 0 0 1 1 0 0 0 0.00 1.00
22 KANNIYAMMAL 1 48 0 IWMI 0 1 0 0 0 0 1 1.00 2.00
23 KRISHNAMOORTHY 1 50 1 AWMI 0 0 1 1 0 0 0 0.00 2.00
24 PECHIAMMAL 1 50 0 AWMI 0 0 0 0 1 0 1 1.00 2.00
25 RUSIYA 1 50 1 AWMI 0 0 1 0 0 0 0 0.00 2.00
26 MUNEER AHAMED 1 45 1 IWMI/DMI 0 0 0 0 1 0 0 0.00 1.00
27 VAIRAMANI 1 52 1 IWMI 0 0 1 1 0 1 0 1.00 2.00
28 BANUBEE 1 38 0 IWMI 1 0 0 0 0 0 0 0.00 1.00
29 PALANI 1 50 1 AWMI 0 0 1 1 0 0 0 0.00 2.00
30 ISMAIL 1 37 1 AWMI 0 0 1 0 0 1 0 1.00 1.00
31 ABDUL RAZAK 1 47 1 ASMI 0 1 1 0 0 0 0 0.00 2.00
32 SARAVANAN 1 54 1 IWMI/DMI 0 1 1 0 0 0 0 0.00 2.00
33 JANAKIRAMAN 1 31 1 ASMI 0 0 1 1 0 0 0 0.00 1.00
34 RAJENDRAN 1 54 1 ASMI 1 0 1 1 0 0 1 1.00 2.00
35 ANTONY 1 38 1 IWMI 0 0 0 0 0 0 0 0.00 1.00
36 RAMAMOORHTY 1 42 1 ASMI 0 0 1 1 1 0 0 0.00 1.00
37 SENTHIL KUMAR 1 33 1 AWMI 0 0 1 1 0 1 0 1.00 1.00
38 VELAYUDAM 1 45 1 ILMI 0 0 1 0 0 0 0 0.00 1.00
39 SEKAR 1 38 1 ASMI 0 0 1 1 0 0 0 0.00 1.00
40 MOORHTY 1 37 1 IWMI 0 0 0 1 0 0 0 0.00 1.00
41 DEVADOSS 1 38 1 AWMI 0 0 1 1 0 0 0 0.00 1.00
42 SHANKARDOSS 1 42 1 ILMI 0 0 0 0 0 0 0 0.00 1.00
43 MANOHARAN 1 46 1 IWMI/DMI 1 0 0 0 0 0 0 0.00 2.00
44 SELVAKUMAR 1 36 1 IWMI 0 0 1 1 0 0 0 0.00 1.00
45 MARIMUTHU 1 35 1 IWMI/DMI 0 0 0 0 1 0 0 0.00 1.00
46 SELVAM 1 50 1 ASMI 0 0 1 0 0 0 0 0.00 2.00
47 RAJENDRAN 1 40 1 AWMI 0 0 1 1 0 1 0 1.00 1.00
48 RAMASUBRAMANIYAM1 52 1 IWMI/DMI/RVMI 0 0 1 1 0 0 0 0.00 2.00
49 SAMSATH 1 35 0 AWMI 0 0 0 0 0 0 0 0.00 1.00
50 VENUGOPAL 1 53 1 ASMI 1 0 0 0 0 0 0 0.00 2.00
51 SHAHUL HAMEED 1 35 1 ILMI 0 0 1 1 1 0 0 0.00 1.00
52 JEYAPRAKASH 1 52 1 AWMI 1 1 0 0 0 0 0 0.00 2.00
53 THILAGAVATHY 1 45 0 IWMI/DMI/RVMI 0 0 0 0 0 0 0 0.00 1.00
54 BALARAMAN 1 48 1 ILMI/DMI 0 0 1 0 0 0 0 0.00 2.00
55 JEYARAMAN 1 38 1 AWMI 0 0 1 1 0 0 0 0.00 1.00
56 SEKAR 1 34 1 AWMI 0 0 1 1 0 0 0 0.00 1.00
57 BALAJI 1 32 1 IWMI/DMI 0 0 0 0 1 0 0 0.00 1.00
58 SEKAR 1 42 1 ASMI 0 0 0 1 0 1 0 1.00 1.00
59 JEGAN 1 30 1 IWMI 0 0 1 1 0 1 0 1.00 1.00
60 SARAVANAKUMAR 1 29 1 AWMI 0 0 1 1 0 0 0 0.00 1.00
61 AYYAMPERUMAL 1 52 1 AWMI 0 0 0 0 0 0 0 0.00 2.00
62 ELANGOVAN 1 38 1 ASMI 0 0 0 0 0 0 0 0.00 1.00
63 AMEER 1 40 1 IWMI/DMI 0 0 1 1 0 0 0 0.00 1.00
GROUP:  1- CASES, 2- CONTROLS
SEX: 0- FEMALE, 1- MALE
DM, HT, SMOKING, ALCOHOL,FAMILY HO:  0- ABSENT, 1- PRESENT
FAMILY HO: FAMILY HISTORY OF PREMATURE CAD
IgGaCL, IgMaCL:  0- NEGATIVE, 1- POSITIVE (aCL-anticardiolipin)
AGE<=45- 1, AGE>45- 2

